β Home
βΉοΈ Info
π§Ύ Overview π Core Facts π₯ Video Blog β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π’ Company Q&A π οΈ Industry Q&A π Competitors π Stock Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risks π§© Segmentationπ§ Tools
β Due DiligenceFinancial Ratios
Pay attention and research significant changes from year to year values. [ ! ]
Fixed Column | Current Ratio | Quick Ratio | Cash Ratio | Days Of Sales Outstanding | Days Of Inventory Outstanding | Operating Cycle | Days Of Payables Outstanding | Cash Conversion Cycle | Gross Profit Margin | Operating Profit Margin | Pretax Profit Margin | Net Profit Margin | Effective Tax Rate | Return On Assets | Return On Equity | Return On Capital Employed | Net Income Per EBT | EBT Per EBIT | EBIT Per Revenue | Debt Ratio | Debt/Equity Ratio | Long Term Debt To Capitalization | Total Debt To Capitalization | Interest Coverage | Cash Flow To Debt Ratio | Company Equity Multiplier | Receivables Turnover | Payables Turnover | Inventory Turnover | Fixed Asset Turnover | Asset Turnover | Operating Cash Flow Per Share | Free Cash Flow Per Share | Cash Per Share | Payout Ratio | Operating Cash Flow / Sales Ratio | Free Cash Flow / Operating Cash Flow Ratio | Cash Flow Coverage Ratio | Short Term Coverage Ratios | Capital Expenditure Coverage Ratio | Dividend Paid And CAPEX Coverage Ratio | Dividend Payout Ratio | Price Book Value Ratio | Price To Book Ratio | Price To Sales Ratio | Price Earnings Ratio | Price To Free Cash Flows Ratio | Price To Operating Cash Flows Ratio | Price Cash Flow Ratio | Price Earnings To Growth Ratio | Price Sales Ratio | Dividend Yield | Enterprise Value Multiple | Price Fair Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-12 | 5.53 | 4.7 | 1.86 | 104.22 | 258.17 | 362.39 | 70.28 | 292.11 | 0.71 | 0.46 | 0.46 | 0.33 | 0.29 | 0.18 | 0.2 | 0.28 | 0.71 | 1 | 0.46 | 0 | 0 | 0 | 0 | -527.75 | 0 | 1.16 | 3.5 | 5.19 | 1.41 | 2.65 | 0.53 | 272.02 | 241.07 | 605.52 | 0.34 | 0.38 | 0.89 | 0 | 0 | 8.79 | 2.43 | 0.34 | 6.06 | 6.06 | 9.84 | 29.73 | 29.03 | 25.73 | 25.73 | 1.57 | 9.84 | 0.01 | 19.31 | 6.06 |
2023-12 | 4.74 | 3.79 | 1.59 | 104.73 | 241.52 | 346.25 | 47.9 | 298.35 | 0.63 | 0.4 | 0.4 | 0.29 | 0.27 | 0.17 | 0.2 | 0.27 | 0.73 | 1.01 | 0.4 | 0.01 | 0.01 | 0 | 0.01 | 0 | 30.47 | 1.19 | 3.49 | 7.62 | 1.51 | 2.64 | 0.58 | 249.16 | 204.03 | 449.17 | 0.4 | 0.37 | 0.82 | 30.47 | 0 | 5.52 | 1.99 | 0.4 | 5.41 | 5.41 | 7.91 | 27 | 26.18 | 21.44 | 21.44 | -2.06 | 7.91 | 0.01 | 17.54 | 5.41 |
2022-12 | 3.15 | 2.46 | 0.52 | 148.48 | 223.95 | 372.43 | 160.82 | 211.61 | 0.62 | 0.42 | 0.42 | 0.3 | 0.3 | 0.2 | 0.26 | 0.37 | 0.7 | 1 | 0.42 | 0.01 | 0.01 | 0 | 0.01 | 8742.77 | 17.3 | 1.31 | 2.46 | 2.27 | 1.63 | 3.26 | 0.67 | 148.41 | 105.1 | 305.88 | 0.37 | 0.19 | 0.71 | 17.3 | 0 | 3.43 | 1.17 | 0.37 | 3.89 | 3.89 | 4.4 | 14.8 | 32.04 | 22.69 | 22.69 | 0.63 | 4.4 | 0.02 | 9.48 | 3.89 |
2021-12 | 3.25 | 2.61 | 0.82 | 129.97 | 225.42 | 355.4 | 164.36 | 191.04 | 0.66 | 0.42 | 0.42 | 0.3 | 0.28 | 0.2 | 0.26 | 0.35 | 0.72 | 0.99 | 0.42 | 0.01 | 0.01 | 0 | 0.01 | 8789.52 | 17.43 | 1.3 | 2.81 | 2.22 | 1.62 | 2.84 | 0.65 | 170.07 | 125.75 | 287.06 | 0.33 | 0.28 | 0.74 | 17.43 | 0 | 3.84 | 1.63 | 0.33 | 5.17 | 5.17 | 6.14 | 20.27 | 29.7 | 21.96 | 21.96 | 0.49 | 6.14 | 0.02 | 13.08 | 5.17 |
2020-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2019-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2018-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2017-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2016-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2015-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2014-12 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |

π Explore more ratios for Chugai Pharmaceutical!
Sign up for free or log in
Have you heard about our short Daily Video Newsletter?
Find out more
Frequently Asked Questions
π What exactly does InsightfulValue do?β
InsightfulValue helps investors analyze public companies with smart tools, highlighting undervalued opportunities based on solid data, not hype.
π How do you identify undervalued stocks?β
We use key metrics like P/E, P/B, cash flow, debt levels, and moreβblended with value-investing principles and proprietary scoring.
π Do you provide real-time stock data?β
We focus on fundamental analysis and not real-time price feeds. Our data is updated regularly for financials, ratios, and risk metrics.
π§ Do I need investing experience to use InsightfulValue?β
Not at all. Our platform is built to be beginner-friendly while still offering advanced tools for experienced investors.
π‘ What makes your analysis different?β
We strip away the noise and show only meaningful dataβSWOTs, margin of safety, 30-year financial trends, peer comparisons, and more.
π° Is there a free version of InsightfulValue?β
Yes! You can explore key features for free. If you want full access to all companies and premium tools, we offer an upgrade.
π Where do you get your financial data?β
We use trusted financial data providers and cross-reference sources to ensure accuracy and depth.
π οΈ What kind of tools are included in premium access?β
Premium users get advanced filters, full financial history, fair value estimations, risk flags, and investment checklists.
π How secure is my data on InsightfulValue?β
We take data privacy seriously. All information is encrypted and we never sell your personal data.
π§Ύ Can I use InsightfulValue for due diligence?β
Absolutely. Our tools are designed to simplify in-depth research and help you confidently evaluate companies before investing.